Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor

The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug develo...

Full description

Saved in:
Bibliographic Details
Published inVirology (New York, N.Y.) Vol. 556; pp. 73 - 78
Main Authors O'Brien, Amornrat, Chen, Da-Yuan, Hackbart, Matthew, Close, Brianna J., O'Brien, Timothy E., Saeed, Mohsan, Baker, Susan C.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors. •Coronavirus 3CLpro activity is efficiently measured using a luciferase-based biosensor.•Small molecule inhibitors of 3CLpro block activation of the biosensor.•Polyclonal antiserum raised against SARS-CoV 3CLpro recognizes SARS-CoV-2 3CLpro in WB and IF assays.
AbstractList The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors. •Coronavirus 3CLpro activity is efficiently measured using a luciferase-based biosensor.•Small molecule inhibitors of 3CLpro block activation of the biosensor.•Polyclonal antiserum raised against SARS-CoV 3CLpro recognizes SARS-CoV-2 3CLpro in WB and IF assays.
AbstractThe need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
Author O'Brien, Timothy E.
Baker, Susan C.
O'Brien, Amornrat
Saeed, Mohsan
Close, Brianna J.
Hackbart, Matthew
Chen, Da-Yuan
Author_xml – sequence: 1
  givenname: Amornrat
  surname: O'Brien
  fullname: O'Brien, Amornrat
  organization: Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
– sequence: 2
  givenname: Da-Yuan
  orcidid: 0000-0002-1957-3330
  surname: Chen
  fullname: Chen, Da-Yuan
  organization: Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
– sequence: 3
  givenname: Matthew
  orcidid: 0000-0001-6244-6292
  surname: Hackbart
  fullname: Hackbart, Matthew
  organization: Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
– sequence: 4
  givenname: Brianna J.
  orcidid: 0000-0002-0563-1464
  surname: Close
  fullname: Close, Brianna J.
  organization: National Emerging Infectious Diseases Laboratories, Boston University, MA, USA
– sequence: 5
  givenname: Timothy E.
  surname: O'Brien
  fullname: O'Brien, Timothy E.
  organization: Department of Mathematics and Statistics, Loyola University Chicago, Chicago, IL, USA
– sequence: 6
  givenname: Mohsan
  orcidid: 0000-0001-8505-7054
  surname: Saeed
  fullname: Saeed, Mohsan
  email: msaeed1@bu.edu
  organization: Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
– sequence: 7
  givenname: Susan C.
  orcidid: 0000-0001-6485-8143
  surname: Baker
  fullname: Baker, Susan C.
  email: sbaker1@luc.edu
  organization: Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33548599$$D View this record in MEDLINE/PubMed
BookMark eNqFUl1rFDEUDVKx2-ovEGQefZntTTIfGcRC2WoVFgRXfQ2ZzJ2aNZtsk5nF_fdm3Fq0IAuXhHDPObnJOWfkxHmHhLykMKdAq4v1fGeCt3MGjM5hKnhCZhSaKgde0BMyAyhYXgnGTslZjGtI57qGZ-SU87IQZdPMyN01DqgH426z1dXnVb7w33KW8cVyG3yGP7cBYzTeZcp1mUq4nRn22RgnvMq23u619U7Z1B9MxDBuDsjMjtr0GFTEvE1Ll7XGR3TRh-fkaa9sxBf3-zn5-v7dl8WHfPnp5uPiapnrqiqHXGOpu06wmraKA22gASwb1beVqnjfsVZ3dU8LoVijad8qUIKJqu-LBtoS-5Kfk8uD7nZsN9hpdENQVm6D2aiwl14Z-W_Hme_y1u9kLXhNKSSB1_cCwd-NGAe5MVGjtcqhH6NkJaVUpP9mx6GFqAteQFUk6Ku_x3qY548lCcAPAB18jAH7BwgFORkv1_K38XIyXsJU07DNI5Y2gxqSdeltxh7hvj1wMdmxMxhk1Aadxs6ElA3ZeXOEf_mIr61xRiv7A_cY134MKSJRUhmZBLmaYjmlktGUSComgTf_Fzh6_S-oVPU2
CitedBy_id crossref_primary_10_1371_journal_ppat_1010265
crossref_primary_10_3390_ijms23010259
crossref_primary_10_3390_v13091814
crossref_primary_10_1128_JVI_02374_20
crossref_primary_10_1128_MCB_00185_21
crossref_primary_10_3390_ijms25052850
crossref_primary_10_1007_s11538_024_01274_4
crossref_primary_10_3390_bios12090710
crossref_primary_10_1021_acs_jmedchem_1c01037
crossref_primary_10_1128_spectrum_02559_21
crossref_primary_10_1128_mbio_00784_22
crossref_primary_10_1016_j_antiviral_2021_105183
crossref_primary_10_1002_pro_4916
crossref_primary_10_1016_j_antiviral_2022_105272
crossref_primary_10_1080_00958972_2021_1965130
crossref_primary_10_1371_journal_pone_0312800
crossref_primary_10_1021_acsbiomedchemau_2c00034
crossref_primary_10_1038_s41598_023_28984_4
crossref_primary_10_1080_22221751_2023_2211688
crossref_primary_10_1128_jvi_00597_23
crossref_primary_10_1126_science_abg5827
Cites_doi 10.1016/j.ijantimicag.2020.106055
10.1126/science.abb4489
10.1016/0003-2697(91)90534-Z
10.1371/journal.pone.0066248
10.1126/scitranslmed.abc5332
10.1006/viro.1997.9010
10.1126/science.abb3405
10.1016/j.bmcl.2008.08.082
10.1128/mBio.01833-20
10.1128/JVI.78.24.13600-13612.2004
10.1128/JVI.02105-13
10.3390/microorganisms8081250
10.1128/JVI.74.17.7911-7921.2000
10.1128/JVI.01265-20
10.1128/JVI.78.18.9977-9986.2004
10.1038/s41586-020-2223-y
ContentType Journal Article
Copyright 2021 Elsevier Inc.
Elsevier Inc.
Copyright © 2021 Elsevier Inc. All rights reserved.
2021 Elsevier Inc. 2021 Elsevier Inc.
Copyright_xml – notice: 2021 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2021 Elsevier Inc. All rights reserved.
– notice: 2021 Elsevier Inc. 2021 Elsevier Inc.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
DOI 10.1016/j.virol.2021.01.010
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
MEDLINE - Academic
AGRICOLA


MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1096-0341
EndPage 78
ExternalDocumentID PMC7837110
33548599
10_1016_j_virol_2021_01_010
S0042682221000180
1_s2_0_S0042682221000180
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GroupedDBID ---
--K
--M
-DZ
-~X
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
3O-
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABEFU
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFGL
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DM4
DU5
EBS
EFBJH
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FA8
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HX~
HZ~
H~9
IHE
IXB
J1W
KOM
LG5
LUGTX
LZ5
M29
M41
MO0
MVM
N9A
O-L
O9-
OAUVE
OD-
OHT
OK1
OO.
OZT
P-8
P-9
P2P
PC.
Q38
Q44
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SIN
SSH
SSI
SSZ
T5K
TN5
UAP
UQL
WH7
WUQ
X7M
XOL
XPP
Y6R
Z5R
ZGI
ZKB
ZMT
ZU3
~G-
~KM
0SF
6I.
AACTN
AAFTH
ABVKL
AFCTW
AFKWA
AJOXV
AMFUW
NCXOZ
RIG
AAIAV
ABLVK
ABYKQ
AFDAS
AFMIJ
AHPSJ
AJBFU
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c665t-ce5cdd8271ba3019090e59afb6a63fd2bcd7f148a29c1fba0a8286ff490b5ef53
IEDL.DBID .~1
ISSN 0042-6822
1096-0341
IngestDate Thu Aug 21 14:25:40 EDT 2025
Mon Jul 21 12:01:28 EDT 2025
Fri Jul 11 06:23:49 EDT 2025
Thu Apr 03 07:00:56 EDT 2025
Thu Apr 24 22:59:53 EDT 2025
Tue Jul 01 02:46:28 EDT 2025
Fri Feb 23 02:39:46 EST 2024
Tue Feb 25 20:07:28 EST 2025
Tue Aug 26 16:31:37 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords SARS-CoV-2
Main protease
Mpro
Protease inhibitors
pGlo biosensor
nsp5
3CLpro
Language English
License This article is made available under the Elsevier license.
Copyright © 2021 Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c665t-ce5cdd8271ba3019090e59afb6a63fd2bcd7f148a29c1fba0a8286ff490b5ef53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6485-8143
0000-0001-6244-6292
0000-0002-0563-1464
0000-0002-1957-3330
0000-0001-8505-7054
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0042682221000180
PMID 33548599
PQID 2487434064
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7837110
proquest_miscellaneous_2511181092
proquest_miscellaneous_2487434064
pubmed_primary_33548599
crossref_primary_10_1016_j_virol_2021_01_010
crossref_citationtrail_10_1016_j_virol_2021_01_010
elsevier_sciencedirect_doi_10_1016_j_virol_2021_01_010
elsevier_clinicalkeyesjournals_1_s2_0_S0042682221000180
elsevier_clinicalkey_doi_10_1016_j_virol_2021_01_010
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-01
PublicationDateYYYYMMDD 2021-04-01
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Virology (New York, N.Y.)
PublicationTitleAlternate Virology
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Schiller, Kanjanahaluethai, Baker (bib17) 1998
Seber, Wild (bib18) 1989
Dai, Zhang, Jiang, Su, Li, Zhao, Xie, Jin, Peng, Liu, Li, Li, Bai, Wang, Cheng, Cen, Hu, Yang, Wang, Liu, Xiao, Jiang, Rao, Zhang, Xu, Yang, Liu (bib1) 2020; 368
Ghosh, Gong, Grum-Tokars, Mulhearn, Baker, Coughlin, Prabhakar, Sleeman, Johnson, Mesecar (bib5) 2008; 18
Jin, Du, Xu, Deng, Liu, Zhao, Zhang, Li, Zhang, Peng, Duan, Yu, Wang, Yang, Liu, Jiang, Yang, You, Liu, Yang, Bai, Liu, Liu, Guddat, Xu, Xiao, Qin, Shi, Jiang, Rao, Yang (bib10) 2020; 582
Kilianski, Mielech, Deng, Baker (bib12) 2013; 87
Li, Kang (bib13) 2020; 8
He, Hu, Huang, Wang, Zhang, Wang, Zhang, Ye (bib9) 2020; 56
Kanjanahaluethai, Baker (bib11) 2000; 74
Drayman, Jones, Azizi, Froggatt, Tan, Maltseva, Chen, Nicolaescu, Dvorkin, Furlong, Kathayat, Firpo, Mastrodomenico, Bruce, Schmidt, Jedrzejczak, Muñoz-Alía, Schuster, Nair, Botten, Brooke, Baker, Mounce, Heaton, Dickinson, Jaochimiak, Randall, Tay (bib2) 2020
Prentice, McAuliffe, Lu, Subbarao, Denison (bib15) 2004; 78
Rathnayake, Zheng, Kim, Perera, Mackin, Meyerholz, Kashipathy, Battaile, Lovell, Perlman, Groutas, Chang (bib16) 2020; 12
Zhang, Lin, Sun, Curth, Drosten, Sauerhering, Becker, Rox, Hilgenfeld (bib19) 2020; 368
Froggatt, Heaton, Heaton (bib3) 2020
Loffredo, Lucer, Chen, O'Connell, Bergqvist, Munawar, Bandara, De Graef, Weeks, Douam, Saeed, Munawar (bib14) 2020
Hattori, Higshi-Kuwata, Raghavaiah, Das, Bulut, Davis, Takamatsu, Matsuda, Takamune, Kishimoto, Okamura, Misumi, Yarchoan, Maeda, Ghosh, Mitsuya (bib8) 2020; 11
Guan, Dixon (bib6) 1991; 192
Harcourt, Jukneliene, Kanjanahaluethai, Bechill, Severson, Smith, Rota, Baker (bib7) 2004; 78
Galbán, Jeon, Bowman, Stevenson, Sebolt, Sharkey, Lafferty, Hoff, Butler, Wigdal, Binkowski, Otto, Zimmerman, Vidugiris, Encell, Fan, Wood, Galbán, Ross, Rehemtulla (bib4) 2013; 8
Kilianski (10.1016/j.virol.2021.01.010_bib12) 2013; 87
Froggatt (10.1016/j.virol.2021.01.010_bib3) 2020
Zhang (10.1016/j.virol.2021.01.010_bib19) 2020; 368
Loffredo (10.1016/j.virol.2021.01.010_bib14) 2020
Kanjanahaluethai (10.1016/j.virol.2021.01.010_bib11) 2000; 74
Ghosh (10.1016/j.virol.2021.01.010_bib5) 2008; 18
Li (10.1016/j.virol.2021.01.010_bib13) 2020; 8
Jin (10.1016/j.virol.2021.01.010_bib10) 2020; 582
Galbán (10.1016/j.virol.2021.01.010_bib4) 2013; 8
Dai (10.1016/j.virol.2021.01.010_bib1) 2020; 368
Guan (10.1016/j.virol.2021.01.010_bib6) 1991; 192
He (10.1016/j.virol.2021.01.010_bib9) 2020; 56
Rathnayake (10.1016/j.virol.2021.01.010_bib16) 2020; 12
Seber (10.1016/j.virol.2021.01.010_bib18) 1989
Schiller (10.1016/j.virol.2021.01.010_bib17) 1998
Hattori (10.1016/j.virol.2021.01.010_bib8) 2020; 11
Harcourt (10.1016/j.virol.2021.01.010_bib7) 2004; 78
Prentice (10.1016/j.virol.2021.01.010_bib15) 2004; 78
Drayman (10.1016/j.virol.2021.01.010_bib2) 2020
References_xml – volume: 56
  start-page: 106055
  year: 2020
  ident: bib9
  article-title: Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: insights from structures of protease and inhibitors
  publication-title: Int. J. Antimicrob. Agents
– volume: 78
  start-page: 9977
  year: 2004
  end-page: 9986
  ident: bib15
  article-title: Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins
  publication-title: J. Virol.
– volume: 368
  start-page: 409
  year: 2020
  end-page: 412
  ident: bib19
  article-title: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors
  publication-title: Science (80-. )
– year: 2020
  ident: bib14
  article-title: The effect of famotidine on SARS-CoV-2 proteases and virus replication
  publication-title: bioRxiv Prepr. Serv. Biol.
– volume: 11
  start-page: 1
  year: 2020
  end-page: 16
  ident: bib8
  article-title: GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection
  publication-title: mBio
– volume: 192
  start-page: 262
  year: 1991
  end-page: 267
  ident: bib6
  article-title: Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase
  publication-title: Anal. Biochem.
– volume: 74
  start-page: 7911
  year: 2000
  end-page: 7921
  ident: bib11
  article-title: Identification of mouse hepatitis virus papain-like proteinase 2 activity
  publication-title: J. Virol.
– volume: 8
  start-page: 1
  year: 2020
  end-page: 18
  ident: bib13
  article-title: Progress in developing inhibitors of sars-cov-2 3c-like protease
  publication-title: Microorganisms
– volume: 368
  start-page: 1331
  year: 2020
  end-page: 1335
  ident: bib1
  article-title: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
  publication-title: Science (80-. )
– start-page: 1
  year: 2020
  end-page: 32
  ident: bib2
  article-title: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
  publication-title: bioRxiv Prepr. Serv. Biol.
– year: 1989
  ident: bib18
  article-title: Nonlinear Regression
– volume: 78
  start-page: 13600
  year: 2004
  end-page: 13612
  ident: bib7
  article-title: Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity
  publication-title: J. Virol.
– year: 2020
  ident: bib3
  article-title: Development of a fluorescence based, high-throughput SARS-CoV-2 3CL pro reporter assay
  publication-title: J. Virol.
– volume: 582
  start-page: 289
  year: 2020
  end-page: 293
  ident: bib10
  article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  publication-title: Nature
– volume: 87
  start-page: 11955
  year: 2013
  end-page: 11962
  ident: bib12
  article-title: Assessing activity and inhibition of middle east respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors
  publication-title: J. Virol.
– volume: 8
  year: 2013
  ident: bib4
  article-title: Imaging proteolytic activity in live cells and animal models
  publication-title: PLoS One
– year: 1998
  ident: bib17
  article-title: Processing of the coronavirus MHV-JHM polymerase polyprotein: identification of precursors and proteolytic products spanning 400 kilodaltons of ORF1a
  publication-title: Virology
– volume: 18
  start-page: 5684
  year: 2008
  end-page: 5688
  ident: bib5
  article-title: Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
  publication-title: Bioorg. Med. Chem. Lett
– volume: 12
  year: 2020
  ident: bib16
  article-title: 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice
  publication-title: Sci. Transl. Med.
– volume: 56
  start-page: 106055
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib9
  article-title: Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: insights from structures of protease and inhibitors
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2020.106055
– volume: 368
  start-page: 1331
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib1
  article-title: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
  publication-title: Science (80-. )
  doi: 10.1126/science.abb4489
– volume: 192
  start-page: 262
  year: 1991
  ident: 10.1016/j.virol.2021.01.010_bib6
  article-title: Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase
  publication-title: Anal. Biochem.
  doi: 10.1016/0003-2697(91)90534-Z
– volume: 8
  year: 2013
  ident: 10.1016/j.virol.2021.01.010_bib4
  article-title: Imaging proteolytic activity in live cells and animal models
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0066248
– volume: 12
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib16
  article-title: 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abc5332
– year: 1998
  ident: 10.1016/j.virol.2021.01.010_bib17
  article-title: Processing of the coronavirus MHV-JHM polymerase polyprotein: identification of precursors and proteolytic products spanning 400 kilodaltons of ORF1a
  publication-title: Virology
  doi: 10.1006/viro.1997.9010
– start-page: 1
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib2
  article-title: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
  publication-title: bioRxiv Prepr. Serv. Biol.
– year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib14
  article-title: The effect of famotidine on SARS-CoV-2 proteases and virus replication
  publication-title: bioRxiv Prepr. Serv. Biol.
– year: 1989
  ident: 10.1016/j.virol.2021.01.010_bib18
– volume: 368
  start-page: 409
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib19
  article-title: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors
  publication-title: Science (80-. )
  doi: 10.1126/science.abb3405
– volume: 18
  start-page: 5684
  year: 2008
  ident: 10.1016/j.virol.2021.01.010_bib5
  article-title: Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
  publication-title: Bioorg. Med. Chem. Lett
  doi: 10.1016/j.bmcl.2008.08.082
– volume: 11
  start-page: 1
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib8
  article-title: GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection
  publication-title: mBio
  doi: 10.1128/mBio.01833-20
– volume: 78
  start-page: 13600
  year: 2004
  ident: 10.1016/j.virol.2021.01.010_bib7
  article-title: Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.24.13600-13612.2004
– volume: 87
  start-page: 11955
  year: 2013
  ident: 10.1016/j.virol.2021.01.010_bib12
  article-title: Assessing activity and inhibition of middle east respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors
  publication-title: J. Virol.
  doi: 10.1128/JVI.02105-13
– volume: 8
  start-page: 1
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib13
  article-title: Progress in developing inhibitors of sars-cov-2 3c-like protease
  publication-title: Microorganisms
  doi: 10.3390/microorganisms8081250
– volume: 74
  start-page: 7911
  year: 2000
  ident: 10.1016/j.virol.2021.01.010_bib11
  article-title: Identification of mouse hepatitis virus papain-like proteinase 2 activity
  publication-title: J. Virol.
  doi: 10.1128/JVI.74.17.7911-7921.2000
– year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib3
  article-title: Development of a fluorescence based, high-throughput SARS-CoV-2 3CL pro reporter assay
  publication-title: J. Virol.
  doi: 10.1128/JVI.01265-20
– volume: 78
  start-page: 9977
  year: 2004
  ident: 10.1016/j.virol.2021.01.010_bib15
  article-title: Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.18.9977-9986.2004
– volume: 582
  start-page: 289
  year: 2020
  ident: 10.1016/j.virol.2021.01.010_bib10
  article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  publication-title: Nature
  doi: 10.1038/s41586-020-2223-y
SSID ssj0004770
Score 2.4642537
Snippet The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and...
AbstractThe need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 73
SubjectTerms 3CLpro
Animals
antiserum
antiviral agents
Antiviral Agents - pharmacology
assays
Biosensing Techniques - methods
biosensors
Coronavirus 3C Proteases - antagonists & inhibitors
Coronavirus 3C Proteases - genetics
Coronavirus 3C Proteases - immunology
Coronavirus 3C Proteases - metabolism
Coronavirus infections
Cross Reactions
drug development
enzyme activity
Immune Sera - immunology
Infectious Disease
Luciferases - genetics
Luciferases - metabolism
Main protease
Mpro
nsp5
pathogenesis
pGlo biosensor
polyclonal antibodies
polyproteins
Protease inhibitors
Protease Inhibitors - pharmacology
proteinase inhibitors
proteinases
Rabbits
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - metabolism
SARS-CoV-2
SARS-CoV-2 - drug effects
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome coronavirus
Severe acute respiratory syndrome-related coronavirus - immunology
Severe acute respiratory syndrome-related coronavirus - metabolism
Viral Nonstructural Proteins - genetics
Viral Nonstructural Proteins - immunology
Viral Nonstructural Proteins - metabolism
virology
Virus Replication - drug effects
Title Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0042682221000180
https://www.clinicalkey.es/playcontent/1-s2.0-S0042682221000180
https://dx.doi.org/10.1016/j.virol.2021.01.010
https://www.ncbi.nlm.nih.gov/pubmed/33548599
https://www.proquest.com/docview/2487434064
https://www.proquest.com/docview/2511181092
https://pubmed.ncbi.nlm.nih.gov/PMC7837110
Volume 556
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemISRe0PguH5OReMTMiZ04fiyFqeNjD4yhvlmOY4-iknRLK7EX_nbu8gVlU5GQ-pLmrKT2-X539f3uCHnho0h7wTOWeGmZzHzKLJhAZhPHAY7TwkfIRv54nE5P5btZMtshk54Lg2mVne1vbXpjrbtvDrrZPFjO58jxBXRBfMO_qKMM43YpFWr5q5-_0zykUgMNBaX7ykNNjhdSyfD8IY6a2p1Io70ena56n38nUf6BSod75HbnTtJx-8Z3yI4v75KbbYPJy3vk_I3HQwKAJ3oy_nTCJtUXFlMx-QAPov5HlwRbUlsWFBkO2EiCYir8GbV0WS0u3QI9dbjf9Gxef28l6WLtMCUGEJAhDBY0n1c1BMTVxX1yevj282TKuiYLzKVpsmLOJ64oslhFuRVILNfcJ9qGPLWpCEWcu0IFiJlsrF0UcsstEs9DkJrniQ-JeEB2y6r0jwgF6Id10CLlXkotIRARRV7kQagscJ3pEYn7yTWuq0COjTAWpk81-2aaFTG4Iobjh4_Iy2HQsi3AsV1c9qtmem4pWEMDALF9mLpumK-7HV2byNSx4eaK1o1IOozcUNx_P_J5r1QGtjSe09jSV-vaxBBESgGeltwiA44yOGdcxyPysFXEYXqEgDA00TDfakNFBwEsKb55p5x_bUqLq0wocAgf_--PekJu4VWb2vSU7K4u1v4ZeG2rfL_Zlvvkxvjo_fQYro5mr38Bq2FDkw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxLvbFjAS3DB1bOfhA4dqS7Wl2x5oi3ozTuLAom2ybXZV9sKf4g8ykxcsrRYJqVJOa1vJzjjfzMTzzRDyynmedpJHzHfKMhW5gFmAQGb9hIM5DlLnIRv54DAYnKgPp_7pCvnZcmEwrbLB_hrTK7RuftlqpLk1GY2Q4wvWBe0bfqL2It5kVu67-SXEbeW7vR1Q8mshdt8f9wesaS3AkiDwpyxxfpKmkQi92EqkU2vufG2zOLCBzFIRJ2mYQaRghU68LLbcIt06y5Tmse8ybBUBuH9LAVxg24S3P37nlagw7Hgv-HhtqaMqqQy5a3jgIbyqWCjydq83h1fd3b-zNv8wg7v3yb3Gf6XbtYgekBWXPyS3646W80fkfMfhqQTYQ3q0_fGI9YtPTFDZH8KNqPveZN3m1OYpRUoFdq6gmHv_hVo6KcbzZIyhAYxXTaJnZ_VMOp4lmIMDJpeh3U1pPCpKiMCLi8fk5EZE_4Ss5kXu1ggFXwMUr2XAnVJaQeQj0ziNMxlGGdeR7hHRCtckTclz7LwxNm1u2zdTacSgRgzHi_fIm27RpK74sXy6arVmWjIrwK8Bi7R8WXjdMlc2EFIaz5TCcHNlm_dI0K1ceFP-fcuX7aYygCF4MGRzV8xKIyBqVRJcO7VkDnjm4A1yLXrkab0RO_FICXGvr0He4cIW7SZgDfPFkXz0taplHkYyBA90_X__1AtyZ3B8MDTDvcP9DXIXR-q8qk2yOr2YuWfgMk7j59UrSsnnm8aEXw37f9U
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detecting+SARS-CoV-2+3CLpro+expression+and+activity+using+a+polyclonal+antiserum+and+a+luciferase-based+biosensor&rft.jtitle=Virology+%28New+York%2C+N.Y.%29&rft.au=O%27Brien%2C+Amornrat&rft.au=Chen%2C+Da-Yuan&rft.au=Hackbart%2C+Matthew&rft.au=Close%2C+Brianna+J&rft.date=2021-04-01&rft.issn=0042-6822&rft.volume=556&rft.spage=73&rft.epage=78&rft_id=info:doi/10.1016%2Fj.virol.2021.01.010&rft.externalDBID=ECK1-s2.0-S0042682221000180&rft.externalDocID=1_s2_0_S0042682221000180
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00426822%2Fcov200h.gif